ArticleJournal of psychiatry & neuroscience : JPN2021
Fatty acid amide hydrolase binding is inversely correlated with amygdalar functional connectivity: a combined positron emission tomography and magnetic resonance imaging study in healthy individuals.
Open access · diamondAbstract read
In one paragraph
Article in Journal of psychiatry & neuroscience : JPN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 21 citations in OpenAlex.
- Functional neuroimaging of fatty acid amide hydrolase inhibition in posttraumatic stress disorder: a randomized clinical trial.Translational psychiatry · 2026Trial
- Research Review: What we have learned about the endocannabinoid system in developmental psychopathology.Journal of child psychology and psychiatry, and allied disciplines · 2025Review
- The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses.Psychological medicine · 2023Review
- Review
- Molecular Imaging in Parkinsonian Disorders-What's New and Hot?Brain sciences · 2022Review
- Fatty acid amide hydrolase levels in brain linked with threat-related amygdala activation.Neuroimage. Reports · 2022Article
- Targeting the Endocannabinoid System in the Treatment of Posttraumatic Stress Disorder: A Promising Case of Preclinical-Clinical Translation?Biological psychiatry · 2022Review
- Higher trait neuroticism is associated with greater fatty acid amide hydrolase binding in borderline and antisocial personality disorders.Scientific reports · 2022Observational
- The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Duncan G J GreenFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Jinhee KimFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Stephen J KishFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Rachel F TyndaleFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Matthew N HillFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Antonio P StrafellaFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Junchao TongFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Tina McCluskeyFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Duncan J WestwoodFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Sylvain HouleFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Nancy J LobaughFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
Isabelle BoileauFrom the Addiction Imaging Research Group, Toronto, Ont., Canada (Green, Westwood, Boileau); the Human Brain Lab, Toronto, Ont., Canada (Kish, Tong, McCluskey); the Campbell Family Mental Health Research Institute, Ont., Canada (Kim, Tyndale, Strafella, Houle, Lobaugh, Boileau); the Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Kim, Kish, Strafella, Tong, McCluskey, Houle, Lobaugh); the Departments of Psychiatry, Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale, Strafella, Houle, Boileau); the Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ont., Canada (Kish, Tyndale); the Institute of Medical Sciences, University of Toronto, Toronto, Ont., Canada (Green, Kish, Houle, Lobaugh, Boileau); the Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada (Hill); the Morton and Gloria Shulman Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ont., Canada (Strafella); and the Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Lobaugh).
University of Calgary · CAToronto Western Hospital · CACentre for Addiction and Mental Health · CAUniversity of Toronto · CA
Funding
Endocannabinoid Metabolism in Cannabis Users: PET Studies with the Novel Probe [1R21DA036024 · NIDA · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI BOILEAU, ISABELLE · 2013 to 2014
$295kNIDA NIH HHS R21 DA036024
Abstract
Background: Upregulation of the endocannabinoid enzyme fatty acid amide hydrolase (FAAH) has been linked to abnormal activity in frontoamygdalar circuits, a hallmark of posttraumatic stress disorder. We tested the hypothesis that FAAH levels in the amygdala were negatively correlated with functional connectivity between the amygdala and prefrontal cortex, subserving stress and affect control. Methods: Thirty-one healthy participants completed positron emission tomography (PET) imaging with the FAAH probe [C-11]CURB, and resting-state functional MRI scans. Participants were genotyped for the FAAH polymorphism rs324420, and trait neuroticism was assessed. We calculated amygdala functional connectivity using predetermined regions of interest (including the subgenual ventromedial prefrontal cortex [sgvmPFC] and the dorsal anterior cingulate cortex [dACC]) and a seed-to-voxel approach. We conducted correlation analyses on functional connectivity, with amygdala [C-11]CURB binding as a variable of interest. Results: The strength of amygdala functional connectivity with the sgvmPFC and dACC was negatively correlated with [C-11]CURB binding in the amygdala (sgvmPFC: r = -0.38, q = 0.04; dACC: r = -0.44; q = 0.03). Findings were partly replicated using the seed-to-voxel approach, which showed a cluster in the ventromedial prefrontal cortex, including voxels in the dACC but not the sgvmPFC (cluster-level, family-wise error rate corrected p < 0.05). Limitations: We did not replicate earlier findings of a relationship between an FAAH polymorphism (rs324420) and amygdala functional connectivity. Conclusion: Our data provide preliminary evidence that lower levels of FAAH in the amygdala relate to increased frontoamygdalar functional coupling. Our findings were consistent with the role of FAAH in regulating brain circuits that underlie fear and emotion processing in humans.
Indexed as
Magnetic Resonance ImagingPositron-Emission TomographyAdultAmidohydrolasesAmygdalaFatty Acid Amide HydrolasesFemaleHealthy VolunteersHumansMalePrefrontal CortexAmidohydrolasesFatty Acid Amide Hydrolases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.